恩帕格利弗洛辛补充剂在心脏症解决方案中通过维持线粒体平静来改善捐赠者心脏的保存
Rui-Lin Liu1,2, Qing-Chun Song1, Kai Yang3
1Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China.
Cardiovascular drugs and therapy
|January 12, 2026
概括
恩帕格利弗洛辛通过减少冷性缺血-再输液损伤来改善供体心脏的保存. 这种-葡萄糖共运输体2 (SGLT2) 抑制剂通过AMPK-Drp1通路保护移植,显示了移植的潜力.
科学领域:
- 心脏病学 心脏病学
- 移植免疫学 移植免疫学
- 线粒体生物学 线粒体生物学
背景情况:
- 心脏移植后的主要移植功能障碍与寒冷缺血和再输血损伤有关.
- 像empagliflozin这样的-葡萄糖共运输体2 (SGLT2) 抑制剂显示出心脏保护作用,但它们在捐赠人心脏保存中的作用尚不清楚.
研究的目的:
- 调查empagliflozin在保护捐赠者心脏免受缺血-再输血损伤方面的有效性.
- 阐明潜在的线粒体信号传递机制,特别是AMPK-Drp1通路.
主要方法:
- 在冷低氧/低氧化下对HL-1心肌细胞的体外评估.
- 在体内评估使用小鼠异型心脏移植模型与24小时冷藏.
- 涉及AMPK和Drp1抑制剂的机制研究.
主要成果:
- 恩帕格利弗洛辛改善了心肌细胞活力,减少了亡,并在体外保留了线粒体功能.
- 在体内,empagliflozin治疗增强了移植功能,减少了心肌损伤和炎症,并减轻了长期慢性排斥.
- 在机械上,empagliflozin激活AMPK,抑制DRp1,促进线粒体融合,并保持形态,影响取决于AMPK-DRp1通路.
结论:
- 恩帕格利弗洛辛通过减轻寒冷缺血-再输液损伤,显著提高了供体心脏的保存.
- 保护作用通过AMPK-Drp1信号轴进行介导,涉及线粒体动力学.
- 恩帕格利弗洛辛证明了超出代谢调节的翻译潜力,可以改善心脏移植的结果.
关键词:
在 AMPKDrp1 信号中.供体心脏的保存 供体心脏的保存恩帕格利弗洛辛 (Empagliflozin) 是一种非常重要的药物.心脏移植心脏移植手术缺血-再输液损伤 缺血-再输液损伤线粒体动力学的动态更多相关视频
08:15Innovative Strategies for Organ Preservation in Heart Transplantation: Uniform Cooling Preservation and Ex-situ Normothermic Perfusion
Published on: November 28, 2025
500
07:14A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
15.1K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:29Cardiomyopathy V: Interprofessional Care
326
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
326
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208